Publicaciones en las que colabora con ARTURO FERNÁNDEZ-CRUZ PÉREZ (16)

2014

  1. Diagnosis of subclinical atherosclerosis in HIV-infected patients: Higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms

    European Journal of Preventive Cardiology, Vol. 21, Núm. 6, pp. 739-748

2013

  1. Authors reply: Association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis

    Journal of Acquired Immune Deficiency Syndromes

  2. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  3. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure

    Journal of Hypertension, Vol. 31, Núm. 11, pp. 2309-2319

2012

  1. Association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis

    Journal of Acquired Immune Deficiency Syndromes

  2. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: A novel anti-atherosclerotic mechanism

    Pharmacological Research, Vol. 66, Núm. 6, pp. 536-543

  3. Factores clínicos y biomarcadores asociados a lesión vascular subclínica en la infección por el virus de la inmunodeficiencia humana

    Medicina Clinica, Vol. 139, Núm. 6, pp. 231-237

  4. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 59, Núm. 2, pp. 141-148

2011

  1. Ezetimibe inhibe la adhesión y la migración de monocitos a través de la ruta de las proteincinasas activadas extracelularmente (p44/p42ERK1/2

    Clínica e investigación en arteriosclerosis, Vol. 23, Núm. 4, pp. 160-167

  2. Ezetimibe inhibe la adhesión y la migración de monocitos a travésde la ruta de las proteincinasas activadas extracelularmente(p44/p42ERK1/2

    Clinica e Investigacion en Arteriosclerosis, Vol. 23, Núm. 4, pp. 160-167

2010

  1. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes

    Diabetes, Vol. 59, Núm. 6, pp. 1292-1301

  2. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

    European Journal of Heart Failure, Vol. 12, Núm. 9, pp. 903-912

2009

  1. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect

    British Journal of Pharmacology, Vol. 156, Núm. 8, pp. 1218-1227

2008

  1. Relationship between plasma levels of soluble CD40L and insulin sensitivity and insulin secretion status in non-diabetic dyslipidemic patients

    Diabetes Research and Clinical Practice, Vol. 79, Núm. 1, pp. 48-55

2006

  1. Activation of peroxisome proliferator-activated receptor-α and -γ In auricular tissue from heart failure patients

    European Journal of Heart Failure, Vol. 8, Núm. 2, pp. 154-161

  2. Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy

    Journal of Nephrology, Vol. 19, Núm. 5, pp. 588-598